| This week's sponsor is Premier Research. | | | Taking the Fight to Rare Cancers
Beating rare cancers demands expertise in oncology and rare diseases. Our white paper shows how adaptive design, study committees, and cross-industry cooperation are fueling real progress. Premier Research. Built for biotech. |
Today's Rundown It’s official—AbbVie dumps Rova-T after another lung cancer fail One year after flop, AstraZeneca's phase 3 lupus trial hits endpoint Esperion's cholesterol-lowering drug clears test in diabetics Immunicum's vaccine fails to beat Pfizer's Sutent in phase 2 Korean prosecutors raid SillaJen over suspected insider trading: report Treating resistant prostate cancer by depriving a key hormone of its 'co-pilot' Featured Story | | | Thursday, August 29, 2019 Lung cancer patients taking Rova-T as a frontline treatment didn't live longer than those on placebo, prompting a data committee to recommend AbbVie halt the study. After failures in second- and third-line settings, AbbVie decided to ditch Rova-T altogether, even though it had paid billions to acquire the drug in 2016. |
|
|---|
|
Top Stories Thursday, August 29, 2019 A phase 3 trial of AstraZeneca’s anifrolumab in systemic lupus erythematosus has met its primary endpoint. The success comes one year after the anti-IFNAR1 antibody failed to move the needle in another late-phase lupus trial. Thursday, August 29, 2019 A phase 2 of Esperion’s bempedoic acid-ezetimibe combination in Type 2 diabetics with high cholesterol has met its primary endpoint. The trial provides evidence the combination can lower cholesterol without negatively affecting blood sugar levels. Thursday, August 29, 2019 Immunicum’s allogeneic dendritic cell vaccine ilixadencel has failed to better the survival rate Pfizer’s Sutent achieved in a phase 2 metastatic renal cell carcinoma trial. As of the cutoff, 63% of patients in the ilixadencel arm were alive. Thursday, August 29, 2019 SillaJen and partner Transgene started August by canning a phase 3 study of their oncolytic virus after an independent data committee deemed it likely to fail. The companies’ stocks went tumbling down—but now, it looks like a SillaJen exec may have avoided that loss by doing some insider trading. Thursday, August 29, 2019 Blocking the enzyme CDK7 could be a new way to overcome metastatic castration-resistant prostate cancer, scientists at the University of Pennsylvania have found. Carrick Therapeutics is planning clinical testing of its CDK7 inhibitor, CT7001. | This week's sponsor is ExL Events. | | | |
Enrollment Showcase | | | October 23-25, 2019 | Chicago, IL | Presented by Biotech Primer BioImmersion: Biotech for the Non-Scientist is a three-day, in-depth course that delves into the scientific details on a broad number of biotechnology topics. Register today! |
|
|---|
|
Resources Sponsored by: Alexander Group From sales headcount and budgets to new product launches and saying “yes” to millennials, hear the top 7 topics that are trending in sales compensation. Sponsored by: Wesco Pharmaceutical Solutions and WBR Insights The regulations and managing processes for hazardous, controlled and rare chemicals and biologics necessary for drug discovery are a huge distraction for R&D labs. Learn from the perspectives of industry executives the pain points and improvements they want in their processes for chemicals and biologics in pharmaceuticals R&D. Sponsored by: Kinaxis Download this life sciences industry spotlight to discover how concurrent planning can help you overcome complex supply chain challenges to drive down costs and improve efficiency. Sponsored by: Patheon, by Thermo Fisher Scientific Patheon, part of Thermo Fisher Scientific, offers advanced API manufacturing technologies such as continuous processing and continuous analytics to deliver high-quality products with well-defined features to meet your timelines and volume requirements. Sponsored by: ICON Understanding the challenges for formulary decision makers and manufacturers. Sponsored by: Veeva This white paper details how leveraging new reporting capabilities, live UAT feedback sessions, and an agile design approach to study builds will save them time and money. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. Latin America Healthcare Compliance Certificate Program September 23-26, 2019 BioBasics: Biotech For The Non-Scientist Oct 22-23, 2019 | San Diego, CA BioImmersion: Biotech for the Non-Scientist October 23-25, 2019 | Chicago, IL 4th FierceBiotech Drug Development Forum October 28-29, 2019 | Boston, MA Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register NOW and start Pre-Boot Camp Preparation! | 